Access Digital Health
CountriesSignalsInterventionsToolsAbout
Log in
← Interventions

Combination therapy for prevention of CVD in those with 30%+ risk

Cost-effectiveness — what published models estimate per unit of health impact
$/DALY
$27–29
WHO-CHOICE modeled
GiveWell
—
no GiveWell model
CE sources
2
Tier A · 39 studies
Source agreement
comparable
within 2.5×
Scope to country:All countries
Loading effectiveness evidence…
Cost-effectiveness

Estimates are sourced in their native units and shown for comparison, not as literal costs. Sources use different frameworks — see each card for what it represents and how it was derived.

Modeled benchmarks ($/DALY)Tier A · standardized benchmark
South-East Asia$29.00View source →
Eastern sub-Saharan Africa$27.00View source →

WHO-CHOICE estimates are modeled at 50% population coverage, compared against the null set (no intervention) under generalized cost-effectiveness analysis. View WHO-CHOICE methodology →

$/DALY sources within 2.5x - treat as comparable, not ranked.

Modeled regional estimates — not realized delivery costs.

Published study estimates ($/DALY)Tier B · context only

Tufts GHCEA · 39 studies, varied methods — explore the spread, not a single number.

Health-system
$360
median · n=33
Mixed
$2,323
median · n=6
Filter the cohort
$434median of 39 studies · IQR $120–$807 · 5 cost-saving
Data completeness: not assessed (no country selected) · Evidence confidence: not assessed (no country selected)

Cost data mapped through broad sector classification — insufficient precision for intervention-specific interpretation. Context only.

Delivery readiness is country-specific. Select a country in the selector above to see its health-system context — workforce density, financing mix, service coverage.
The figures above are published benchmarks. To build an investment case for your own context — local unit costs, target population, coverage assumptions — model it directly. Select a country first to carry its context into the model.
Choose a country to model →
Looking for supply/market data for Combination therapy for prevention of CVD in those with 30%+ risk? Select a country above, then open its intelligence page.